Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Source : https://www.nature.com/articles/s43018-021-00174-z
Cyclin-dependent kinases (CDKs) 4 and 6 inhibitors (CDK4/6is) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that...
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900143/
Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety...
Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer
Source : https://clincancerres.aacrjournals.org/content/early/2021/02/17/1078-0432.CCR-20-4879.abstract
Purpose: PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients...
0pubmed
Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
Johnston et al demonstrated that abemaciclib in addition to postoperative endocrine therapy is beneficial for treating high-risk hormone receptor (HR)-positive human epidermal growth factor receptor type 2 (HER2)-negative breast cancer....